A Message from our Founder on International Clinical Trials Day

At MMS, we take great pride in our work as a data CRO and hence May 20th has a special significance for us as International Clinical Trials Day.
Clinical trials are the backbone of drug development and allow our industry to look at the efficacy and safety of medications in an unbiased manner. The entire pharmaceutical industry is deeply indebted to patients who participate in clinical trials and allow us to provide the data for various therapies on the market. This day is the basis for many life-saving therapies, including the recent COVID vaccines, without which all of mankind would have had a major setback.
Our core services at MMS and our values to improve patient lives align with this day. As a quality-focused data CRO and a pioneer in data transparency, every colleague at MMS recognizes and appreciates clinical trial data as the foundation of our work and strives hard to make this meaningful from a clinical and regulatory perspective. Whether we are creating a dataset, writing a study report or submission, anonymizing data or reports, or auditing clinical trial sites, we strive to honor those patients contributing to the clinical trial pool with our diligence and efforts.
Today, on International Clinical Trials Day, we pause, reflect and are grateful to have an opportunity to support patients across a spectrum of therapeutic areas, including rare diseases, to the best of our abilities and serve humanity in our own little way. We also celebrate all MMS colleagues who directly and indirectly support clinical trials and patients worldwide. Take a moment today to reflect and celebrate your effort and personal mission to this important work.
Dr. Uma Sharma is the founder and Chief Scientific Officer at MMS.
To learn more about MMS services, visit our website.
Suggested For You

perspectives
May 21st, 2024
Psychedelics and Regulatory Considerations Part II: A Shift in Lexicon and Implications of “Nonmedical Use” On Labelling

perspectives
May 10th, 2024
Psychedelics in Drug Development and Regulatory Considerations Part I: Benefit-Risk

perspectives
November 11th, 2023
The Silent Battle: Exploring PTSD Treatments and Psychedelic Research in Veteran Care

perspectives
October 26th, 2023
Psychedelic Drug Development is Here: What You Need to Know

perspectives
February 24th, 2023
Orphan Drug Designations in the EU: Recent Rare Disease Treatment Updates

perspectives
January 10th, 2022
New FDA Guidance to Support Ultra-Rare Disease Drug Development

perspectives
December 1st, 2021
FDA Expedited Program Designations to Support Rare Disease Drug Development

perspectives
September 15th, 2021
Challenges of Rare Disease Drug Development Programs

perspectives
June 13th, 2019
Developing Treatments for Rare Diseases – Reviewing Recent FDA Draft Guidances

perspectives
February 28th, 2019
How #OneMMS Actively Supports Rare Disease Day

perspectives
June 14th, 2018
Society needs to change to embrace open discussions on suicide

perspectives
June 27th, 2017
Alzheimer’s Awareness and the Future of Clinical Development: Face the Scope and Don’t Lose Hope